[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346082-105":59,"doc-detail-346082-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","association-between-menopausal-hormone-therapy-and-the-risk-of-urologic-cancer-a-national-population-based-retrospective-cohort-study-in-korea","Association Between Menopausal Hormone Therapy and the Risk of Urologic Cancer - A National Population-Based Retrospective Cohort Study in Korea","","Menopausal hormone therapy (MHT) and its relationship with urologic cancer risk in Korean postmenopausal women were evaluated using Korea’s Health Insurance Database. Health insurance data from January 1, 2002 to December 31, 2019 were analyzed, with women older than 40 categorized into exposed (MHT users) and unexposed (non-users) cohorts. Cox proportional hazards models assessed cancer risk by MHT formulation. MHT was linked to increased kidney cancer incidence for oral and topical oestrogen and reduced bladder cancer incidence with tibolone.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/association-between-menopausal-hormone-therapy-and-the-risk-of-urologic-cancer-a-national-population-based-retrospective-cohort-study-in-korea/346082/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/association-between-menopausal-hormone-therapy-and-the-risk-of-urologic-cancer-a-national-population-based-retrospective-cohort-study-in-korea/346082.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main objective of this study?","Question",{"text":113,"@type":114},"To evaluate the relationship between menopausal hormone therapy and the risk of urologic cancer in women using Korea’s Health Insurance Database.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were participants selected and grouped in the analysis?",{"text":118,"@type":114},"Health insurance data from 2002–2019 were used, and postmenopausal women aged over 40 were divided into an exposed cohort (MHT users) and an unexposed cohort (non-users) based on MHT exposure status.",{"name":120,"@type":111,"acceptedAnswer":121},"Which MHT formulations were associated with kidney cancer and bladder cancer risk?",{"text":122,"@type":114},"Oral and topical oestrogen were significantly associated with increased kidney cancer incidence, while tibolone was significantly associated with decreased bladder cancer incidence. Other formulations were not associated with these outcomes.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},346082,1790164383,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","J Korean Med Sci. 2026 Aug 31;41(34):e225 [https://doi.org/10.3346/jkms.2026.41.e225](https://doi.org/10.3346/jkms.2026.41.e225)[ ](https://doi.org/10.3346/jkms.2026.41.e225)eISSN 1598-6357·pISSN 1011-8934  \nOriginal Article  \nClinical Medicine in Other Specialties  \nReceived: Aug 15, 2025  \nAccepted: Dec 9, 2025  \nPublished online: May 20, 2026  \nAddress for Correspondence:  \nJae Yoon Kim, MD, PhD  \nDepartment of Urology, Sanggye Paik Hospital, Inje University College of Medicine, 1342 Dongil-ro, Nowon-gu, Seoul 01757, Korea. [Email: guidepro@hanmail.net](Email: guidepro@hanmail.net)  \n© 2026 The Korean Academy of Medical Sciences.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nORCID iDs  \nJin-Sung Yuk  [https://orcid.org/0000-0002-5478-634X](https://orcid.org/0000-0002-5478-634X)[ ](https://orcid.org/0000-0002-5478-634X)[Sang-Hee Yoon](Sang-Hee Yoon)  [https://orcid.org/0000-0002-5723-5105](https://orcid.org/0000-0002-5723-5105)[ ](https://orcid.org/0000-0002-5723-5105)Dae Yeon Cho  [https://orcid.org/0000-0002-0710-5070](https://orcid.org/0000-0002-0710-5070)[ ](https://orcid.org/0000-0002-0710-5070)Nuri Oh  [https://orcid.org/0009-0005-3777-2770](https://orcid.org/0009-0005-3777-2770)[ ](https://orcid.org/0009-0005-3777-2770)Jae Yoon Kim  [https://orcid.org/0000-0002-2614-6070](https://orcid.org/0000-0002-2614-6070)  \nAssociation Between Menopausal Hormone Therapy and the Risk of Urologic Cancer: A National Population-Based Retrospective Cohort Study in Korea  \nJin-Sung Yuk ,1 Sang-Hee Yoon ,1 Dae Yeon Cho ,2 Nuri Oh ,3 and Jae Yoon Kim  2,4  \n1Department of Obstetrics and Gynecology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea  \n2Department of Urology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea 3Department of Chemistry and Biology, Korea Science Academy of Korea Advanced Institute of Science and Technology, Busan, Korea  \n4Graduate School, Korea University College of Medicine, Seoul, Korea  \nABSTRACT  \nBackground: This study aimed to evaluate the relationship between menopausal hormone therapy (MHT) and the risk of urologic cancer in women using the Health Insurance Database in Korea.  \nMethod: We collected Health insurance data from the Health Insurance Review and Assessment Service in Korea between January 1, 2002 and December 31, 2019. Postmenopausal women aged > 40 years were grouped based on MHT exposure status, forming an exposed (MHT users) and an unexposed (non-users) cohort. Types of  \nMHT included tibolone, combined oestrogen plus progestin by the manufacturer (CEPM) or physician (CEPP), and oral and topical oestrogen. Patient characteristics, including age, body mass index (BMI), Charlson comorbidity index, socioeconomic status, residency region, smoking status, alcohol history, physical exercise pattern, reproductive factors such as age at menarche and at menopause, parity, and the period from menopause to inclusion in the study, were reviewed. We performed a Cox proportional hazard analysis to clarify the risk of urologic cancer associated with MHT.  \nResults: Among 2,506,271 participants who had a national health check, 557,031 did not receive MHT and 204,130 received MHT. The median age and BMI of patients were 56 (52–62) and 23.8 (21.9–25.9) kg/m2, respectively. According to MHT types, 104,089 patients were treated with tibolone, 65,597 with CEPM, 29,357 with oral oestrogen, 3,913 with CEPP, and 1,174 with topical oestrogen. Among women on MHT, the incidence of kidney cancer was significantly associated with oral (hazard ratio [HR], 1.36; 95% confidence interval [CI], 1.062–1.735) and topical oestrogen (HR, 2.84; 95% CI, 1","cbCaiuWY9RHQnvr0","https://ap.wps.com/l/cbCaiuWY9RHQnvr0","pdf",984018,"English","# Abstract\n## Background\n## Method\n## Results\n## Conclusion\n# Introduction\n## Menopause symptoms and MHT use\n## Prior evidence of urologic cancer risk","[{\"question\":\"What was the main objective of this study?\",\"answer\":\"To evaluate the relationship between menopausal hormone therapy and the risk of urologic cancer in women using Korea’s Health Insurance Database.\"},{\"question\":\"How were participants selected and grouped in the analysis?\",\"answer\":\"Health insurance data from 2002–2019 were used, and postmenopausal women aged over 40 were divided into an exposed cohort (MHT users) and an unexposed cohort (non-users) based on MHT exposure status.\"},{\"question\":\"Which MHT formulations were associated with kidney cancer and bladder cancer risk?\",\"answer\":\"Oral and topical oestrogen were significantly associated with increased kidney cancer incidence, while tibolone was significantly associated with decreased bladder cancer incidence. Other formulations were not associated with these outcomes.\"}]","Association Between Menopausal Hormone Therapy and the Risk of Urologic Cancer - A National Population-Based Retrospective Cohort Study in Korea | PDF",1790060021,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bed6630ce23c4610612d07cc65f3b85e.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd5ccd2ed436ee0de26032ab52f1b2b5.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/770f50a6905550fe83876e329599f989.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e30ed3e351a113f34daf0d30bea5d4e3.webp",980,1306]